Cargando…

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, the limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Granda-Díaz, Rocío, Martínez-Pérez, Alejandra, Aguilar-García, Candelaria, Rodrigo, Juan P., García-Pedrero, Juana M., Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466776/ https://www.ncbi.nlm.nih.gov/pubmed/37649037 http://dx.doi.org/10.1186/s12943-023-01845-4

Ejemplares similares

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022)

Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

A crucial role for HVEM and BTLA in preventing intestinal inflammation
por: Steinberg, Marcos W., et al.
Publicado: (2008)

Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
por: Lan, Xiuwen, et al.
Publicado: (2017)

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
por: Demerlé, Clemence, et al.
Publicado: (2021)

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren’s Syndrome
por: Small, Annabelle, et al.
Publicado: (2022)

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses
por: Spodzieja, Marta, et al.
Publicado: (2017)

BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
por: Yu, Xueping, et al.
Publicado: (2019)

HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160
por: Liu, Weifeng, et al.
Publicado: (2021)

The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
por: Yang, Bin, et al.
Publicado: (2016)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
Publicado: (2023)

CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA
por: Flynn, Rachel, et al.
Publicado: (2013)

Correction: The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
por: Yang, Bin, et al.
Publicado: (2017)

The BTLA–HVEM–CD5 Immunoregulatory Axis–An Instructive Mechanism Governing pTreg Cell Differentiation
por: Bourque, Jessica, et al.
Publicado: (2019)

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies
por: Kuncewicz, Katarzyna, et al.
Publicado: (2020)

The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota
por: Kou, Yanbo, et al.
Publicado: (2022)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure
por: Xu, Huan, et al.
Publicado: (2012)

Distinct Changes of BTLA and HVEM Expressions in Circulating CD4(+) and CD8(+) T Cells in Hepatocellular Carcinoma Patients
por: Liu, Jiayu, et al.
Publicado: (2018)

Allosteric regulation of binding specificity of HVEM for CD160 and BTLA ligands upon G89F mutation
por: Shrestha, Rojan, et al.
Publicado: (2021)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

BTLA Interaction with HVEM Expressed on CD8(+) T Cells Promotes Survival and Memory Generation in Response to a Bacterial Infection
por: Steinberg, Marcos W., et al.
Publicado: (2013)

Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients
por: Wang, Zijie, et al.
Publicado: (2017)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis
por: Mintz, Michelle A., et al.
Publicado: (2019)

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
por: Li, Xiangmin, et al.
Publicado: (2020)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors
por: Sun, Wei-Zen, et al.
Publicado: (2023)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
por: Wakeley, Michelle E., et al.
Publicado: (2023)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

The BTLA and PD‐1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells
por: Hwang, Hyun J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bke5hkm56gcnca6461qrmfj3l5